{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:12:22Z","timestamp":1782306742179,"version":"3.54.5"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,15]]},"DOI":"10.1097\/tp.0b013e31825f0fbe","type":"journal-article","created":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T11:11:59Z","timestamp":1349349119000},"page":"885-893","source":"Crossref","is-referenced-by-count":23,"title":["The Pathophysiology of Endothelin in Complications After Solid Organ Transplantation"],"prefix":"10.1097","volume":"94","author":[{"given":"Amresh","family":"Raina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Benza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1600-6143.2011.03539.x","article-title":"Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success.","volume":"11","author":"Lodhi","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.phrs.2011.01.014","article-title":". Role of endothelin in the cardiovascular system.","volume":"63","author":"Rodriguez-Pascual","year":"2011","journal-title":"Pharmacol Res"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","article-title":". Polar secretion of endothelin-1 by cultured endothelial cells.","volume":"267","author":"Wagner","year":"1992","journal-title":"J Biol Chem"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pharmthera.2005.08.012","article-title":"Endothelin receptor antagonists.","volume":"110","author":"Motte","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"H1902","DOI":"10.1152\/ajpheart.01141.2009","article-title":"K O-Uchi, Morimoto S, et al.. Role of Ca(2)calmodulin-dependent protein kinase II in the regulation of the cardiac L-type Ca(2) current during endothelin-1 stimulation.","volume":"298","author":"Komukai","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/bj2720761","article-title":"Stimulation of the hydrolysis of phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine by endothelin, a complete mitogen for Rat-1 fibroblasts.","volume":"272","author":"MacNulty","year":"1990","journal-title":"Biochem J"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.101.2.142","article-title":". Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist.","volume":"101","author":"MacCarthy","year":"2000","journal-title":"Circulation"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"H596","DOI":"10.1152\/ajpheart.2001.281.2.H596","article-title":". Inotropic response of rabbit ventricular myocytes to endothelin-1: difference from isolated papillary muscles.","volume":"281","author":"Talukder","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R10-1-20210129","first-page":"195","article-title":"Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure Int J C","volume":"85","author":"Kalra","year":"2002","journal-title":"ardiol"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/ndt\/gfq534","article-title":". Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice.","volume":"26","author":"Schildroth","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":". Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":". The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1183\/09031936.00058409","article-title":". Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.","volume":"34","author":"Lavelle","year":"2009","journal-title":"Eur Respir J"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":". Avosentan for overt diabetic nephropathy.","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(86)90355-7","article-title":". Cyclosporin in therapeutic doses increases renal allograft vascular resistance.","volume":"2","author":"Curtis","year":"1986","journal-title":"Lancet"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00007890-198707000-00027","article-title":". Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function.","volume":"44","author":"English","year":"1987","journal-title":"Transplantation"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0002-9343(88)80331-0","article-title":". Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent.","volume":"85","author":"Curtis","year":"1988","journal-title":"Am J Med"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004872-198807000-00001","article-title":"Cyclosporine A and hypertension.","volume":"6","author":"Schachter","year":"1988","journal-title":"J Hypertens"},{"key":"R22-1-20210129","first-page":"176","article-title":"Cardiovascular disease after renal transplantation.","volume":"20","author":"Kasiske","year":"2000","journal-title":"Semin Nephrol"},{"issue":"suppl 1","key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ndt\/10.supp1.95","article-title":"Hypertension and ischaemic heart disease in renal transplant recipients.","volume":"10","author":"Raine","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"R24-1-20210129","first-page":"791","article-title":"Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations.","volume":"7","author":"McNally","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199009133231101","article-title":". Cyclosporine-induced sympathetic activation and hypertension after heart transplantation.","volume":"323","author":"Scherrer","year":"1990","journal-title":"N Engl J Med"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/01.HYP.27.6.1341","article-title":". Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates.","volume":"27","author":"Bartholomeusz","year":"1996","journal-title":"Hypertension"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1523-1755.1998.00744.x","article-title":"Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study.","volume":"53","author":"Opelz","year":"1998","journal-title":"Kidney Int"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1046\/j.1523-1755.2001.0590031158.x","article-title":". Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients.","volume":"59","author":"Cosio","year":"2001","journal-title":"Kidney Int"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1046\/j.1523-1755.1999.00752.x","article-title":". Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology.","volume":"56","author":"Cosio","year":"1999","journal-title":"Kidney Int"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1523-1755.2005.00558.x","article-title":". Posttransplantation chronic renal damage in nonrenal transplant recipients.","volume":"68","author":"Stratta","year":"2005","journal-title":"Kidney Int"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":". Chronic renal failure after transplantation of a nonrenal organ.","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.healun.2011.08.003","article-title":". The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011.","volume":"30","author":"Stehlik","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R34-1-20210129","first-page":"S70","article-title":"Cyclosporine-induced renal dysfunction in experimental animals and humans.","volume":"52","author":"Remuzzi","year":"1995","journal-title":"Kidney Int Suppl"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","article-title":"New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.","volume":"293","author":"Bobadilla","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1600-6143.2004.00446.x","article-title":". Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.","volume":"4","author":"Mota","year":"2004","journal-title":"Am J Transplant"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ki.1996.415","article-title":". Chronic cyclosporine nephropathy: the Achilles heel of immunosuppressive therapy.","volume":"50","author":"Bennett","year":"1996","journal-title":"Kidney Int"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1523-1755.2004.05410.x","article-title":". The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging.","volume":"65","author":"Joosten","year":"2004","journal-title":"Kidney Int"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00075200-200306000-00007","article-title":"Advances in the study of chronic allograft rejection.","volume":"8","author":"Orosz","year":"2003","journal-title":"Curr Opin Organ Transplant"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.TP.0000068481.98801.10","article-title":". Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies.","volume":"75","author":"Scherer","year":"2003","journal-title":"Transplantation"},{"key":"R42-1-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1600-6143.2011.03505.x","article-title":"Chronic progressive calcineurin nephrotoxicity: an overstated concept.","volume":"11","author":"Matas","year":"2011","journal-title":"Am J Transplant"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":". Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids.","volume":"7","author":"Buchler","year":"2007","journal-title":"Am J Transplant"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":". Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.tp.0000256179.14038.e2","article-title":". Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.","volume":"83","author":"Kandaswamy","year":"2007","journal-title":"Transplantation"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00007890-199110000-00012","article-title":". Improved outcome of cadaveric renal transplantation due to calcium channel blockers.","volume":"52","author":"Palmer","year":"1991","journal-title":"Transplantation"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1172\/JCI115293","article-title":"Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells.","volume":"88","author":"Bunchman","year":"1991","journal-title":"J Clin Invest"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1046\/j.1523-1755.1998.00132.x","article-title":". Endothelin release by rabbit proximal tubule cells: modulatory effects of cyclosporine A, tacrolimus, HGF and EGF.","volume":"54","author":"Haug","year":"1998","journal-title":"Kidney Int"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0014-2999(90)90610-I","article-title":"Stimulatory effect of cyclosporine A on endothelin secretion by a cultured renal epithelial cell line, LLC-PK1 cells.","volume":"180","author":"Nakahama","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"R50-1-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(93)90066-Q","article-title":". Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cells.","volume":"233","author":"Takeda","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"R51-1-20210129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1399-0012.2005.00357.x","article-title":". Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients.","volume":"19","author":"Cauduro","year":"2005","journal-title":"Clin Transplant"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/07853890410018925","article-title":"Role of endothelin in fibrosis and anti-fibrotic potential of bosentan.","volume":"37","author":"Clozel","year":"2005","journal-title":"Ann Med"},{"issue":"suppl 3","key":"R53-1-20210129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2362.2006.01689.x","article-title":"Role of endothelin and endothelin receptor antagonists in renal disease.","volume":"36","author":"Neuhofer","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"R54-1-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1165\/rcmb.2006-0353OC","article-title":". Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-1.","volume":"37","author":"Jain","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R55-1-20210129","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis.","volume":"112","author":"Kalluri","year":"2003","journal-title":"J Clin Invest"},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0002-9440(10)62984-7","article-title":". Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition.","volume":"167","author":"Slattery","year":"2005","journal-title":"Am J Pathol"},{"key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/ki.1993.259","article-title":". International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.","volume":"44","author":"Solez","year":"1993","journal-title":"Kidney Int"},{"key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1523-1755.1999.00288.x","article-title":". Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.","volume":"55","author":"Benigni","year":"1999","journal-title":"Kidney Int"},{"key":"R60-1-20210129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1524-6175.2007.07244.x","article-title":". Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.","volume":"9","author":"Black","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","article-title":". Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.","volume":"109","author":"Goddard","year":"2004","journal-title":"Circulation"},{"key":"R62-1-20210129","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/ndt\/gfm364","article-title":". Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.","volume":"22","author":"Dhaun","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R64-1-20210129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.HYP.0000173426.06832.b5","article-title":". Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.","volume":"46","author":"Vaneckova","year":"2005","journal-title":"Hypertension"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1523-1755.2002.00424.x","article-title":". Post-transplant renal function in the first year predicts long-term kidney transplant survival.","volume":"62","author":"Hariharan","year":"2002","journal-title":"Kidney Int"},{"key":"R66-1-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","article-title":". Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A.","volume":"57","author":"Binet","year":"2000","journal-title":"Kidney Int"},{"key":"R67-1-20210129","first-page":"480","article-title":"Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1.","volume":"114","author":"Bloom","year":"1993","journal-title":"Surgery"},{"key":"R68-1-20210129","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI116440","article-title":"Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.","volume":"91","author":"Lanese","year":"1993","journal-title":"J Clin Invest"},{"key":"R69-1-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0014-2999(95)00591-9","article-title":"Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670.","volume":"294","author":"Brooks","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ki.1994.15","article-title":"Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction.","volume":"45","author":"Kivlighn","year":"1994","journal-title":"Kidney Int"},{"key":"R71-1-20210129","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease.","volume":"17","author":"Dhaun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R72-1-20210129","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":". Avosentan reduces albumin excretion in diabetics with macroalbuminuria.","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R74-1-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.V102387","article-title":". The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the Fisher to Lewis model.","volume":"10","author":"Orth","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R75-1-20210129","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1681\/ASN.V591718","article-title":". Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity.","volume":"5","author":"Hunley","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R76-1-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00007890-199909270-00005","article-title":". Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist.","volume":"68","author":"Braun","year":"1999","journal-title":"Transplantation"},{"key":"R77-1-20210129","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/01.CIR.0000015606.69079.27","article-title":". Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation.","volume":"105","author":"Ferri","year":"2002","journal-title":"Circulation"},{"key":"R78-1-20210129","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/00007890-199906270-00007","article-title":". Inhibition of endothelin-converting enzyme attenuates transplant vasculopathy and rejection in rat cardiac allografts.","volume":"67","author":"Simonson","year":"1999","journal-title":"Transplantation"},{"key":"R79-1-20210129","first-page":"835","article-title":". Expression of endothelin-1 and effects of an endothelin receptor antagonist, TAK-044, at reperfusion after cold preservation in a canine lung transplantation model.","volume":"17","author":"Mizutani","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"R82-1-20210129","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.healun.2006.08.007","article-title":". Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans.","volume":"25","author":"Antus","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R83-1-20210129","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/jlts.2003.50191","article-title":". Endothelin-A receptor antagonist reduces microcirculatory disturbances and transplant dysfunction after partial liver transplantation.","volume":"9","author":"Palmes","year":"2003","journal-title":"Liver Transpl"},{"key":"R84-1-20210129","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2004.11.019","article-title":". Amelioration of microcirculatory damage by an endothelin A receptor antagonist in a rat model of reversible acute liver failure.","volume":"42","author":"Palmes","year":"2005","journal-title":"J Hepatol"},{"key":"R85-1-20210129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.healun.2011.08.002","article-title":". Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2011 annual reports.","volume":"30","author":"Hertz","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R86-1-20210129","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":". Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"R87-1-20210129","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":". Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R89-1-20210129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2010.120","article-title":". Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.","volume":"88","author":"Spence","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007890-201211150-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:01:58Z","timestamp":1643500918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201211150-00001"}},"subtitle":["A Potential Novel Therapeutic Role for Endothelin Receptor Antagonists"],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31825f0fbe","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11,15]]}}}